The purpose of this study was to measure the electrocardiographic (ECG) effects of WCK 2349 (the L-alanine ester prodrug of levonadifloxacin) at a supratherapeutic oral dose of 2,600 mg. A total of 48 healthy volunteers were randomized to treatment with placebo, WCK 2349, or oral moxifloxacin, 400 mg, in a crossover-designed thorough QT study. A supratherapeutic mean maximum levonadifloxacin concentration (C ) of 43.3 μg/mL was achieved at 3.1 hours. A therapeutic dose of 1,000 mg b.i.d. in a previous study in patients resulted in a C of 17.8 μg/mL. WCK 2349 exerted no significant effect on baseline- and placebo-corrected QTcF (QT interval corrected for heart rate (HR) by the Fridericia formula), QRS, or PR interval. HR was transiently accelerated by a maximum of 14.4 (95% confidence interval, 11.80-16.92) beats per minute (bpm) at 3 hours. Concentration-effect modeling predicted a mean increase of 8.0 bpm at C at the standard therapeutic dose. A therapeutic dose of 1,000 mg b.i.d. of WCK 2349 is not expected to cause clinically significant ECG effects, except for a possible transient increase in HR, which seems to be clinically insignificant.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342240 | PMC |
| http://dx.doi.org/10.1111/cts.12594 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrated virtual screening and MD simulation study to discover potential inhibitors of mycobacterial electron transfer flavoprotein oxidoreductase.
PLoS One
November 2024
Biological Sciences, Superior University, Lahore, Pakistan.
Tuberculosis (TB) continues to be a major global health burden, with high incidence and mortality rates, compounded by the emergence and spread of drug-resistant strains. The limitations of current TB medications and the urgent need for new drugs targeting drug-resistant strains, particularly multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, underscore the pressing demand for innovative anti-TB drugs that can shorten treatment duration. This has led to a focus on targeting energy metabolism of Mycobacterium tuberculosis (Mtb) as a promising approach for drug discovery.
View Article and Find Full Text PDFBacterial profile of wound site infections and evaluation of risk factors for sepsis among road traffic accident patients from Apex Trauma Centre, Northern India.
Access Microbiol
October 2024
Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Article Synopsis
- Trauma and accidental injuries are a major global health concern, with India experiencing the highest road accident deaths, accounting for 11% of the world's total.
- A study from January 2023 to January 2024 analyzed wound samples from road traffic accident (RTA) patients in a northern Indian tertiary care center to assess bacterial contamination and antibiotic susceptibility.
- Out of 189 samples, 52.38% showed microbial growth, predominantly Gram-negative bacilli, with none being resistant to colistin; 26.45% of patients developed sepsis, linked to raised procalcitonin levels and low Glasgow Coma Scale scores.
Serum Pharmacokinetics and Bone Penetration of Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin in Wistar Rats.
Microb Drug Resist
November 2024
New Drug Discovery Research, Wockhardt Research Centre, Chhatrapati Sambhajinagar, India.
Levonadifloxacin (IV) and alalevonadifloxacin (oral) are novel broad-spectrum anti-methicillin-resistant () agents based on novel benzoquinolizine core. Both are recently approved in India for the treatment of acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The present investigation reports the findings from preclinical pharmacokinetic (PK) studies that support the development of levonadifloxacin as a treatment option for bone and joint infections (BJIs).
View Article and Find Full Text PDFSusceptibility of clinical isolates of novel pathogen to novel benzoquinolizine fluoroquinolone levonadifloxacin.
JAC Antimicrob Resist
August 2024
Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Article Synopsis
- The study focuses on evaluating the effectiveness of levofloxacin and levonadifloxacin against a newly identified pathogen that has shown increasing resistance to levofloxacin.
- 116 clinical isolates were analyzed, revealing that approximately 40% were resistant to levofloxacin, but both antibiotics had a 98% inhibition rate against the tested isolates.
- Although both antibiotics showed similar susceptibility, levonadifloxacin had lower minimum inhibitory concentrations (MICs), suggesting it might be a better option; further research is needed to confirm its clinical use.
Efficacy and Safety of Oral and IV Levonadifloxacin Therapy in Management of Bacterial Infections: Findings of a Prospective, Observational, Multi-center, Post-marketing Surveillance Study.
Cureus
February 2024
Medical Affairs, Wockhardt Ltd., Mumbai, IND.
Background Antimicrobial resistance by bacteria poses a substantial threat to morbidity and mortality worldwide, and treatment of resistant infections is a challenge for the treating clinician. Levonadifloxacin is a novel broad-spectrum agent belonging to the benzoquinolizine subclass of quinolone, which can be used by both oral and intravenous administration for the treatment of infections caused by gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). Patients and methods This prescription event monitoring study captured data from 1266 patients receiving levonadifloxacin (oral and/or IV) in a real-world setting to assess the safety and efficacy in the treatment of various bacterial infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!